ChemoCentryx Amends Approval Application for Avacopan

ChemoCentryx Amends Approval Application for Avacopan

298747

ChemoCentryx Amends Approval Application for Avacopan

ChemoCentryx has filed an amendment to its application seeking approval of avacopan, an investigational therapy for the treatment of ANCA-associated vasculitis (AAV). The filing addresses the issues raised by an advisory committee of independent medical experts during a recent meeting with the U.S. Food and Drug Administration (FDA). That panel provided the agency with non-binding recommendations. At that meeting, the committee voted 10–8 on whether avacopan’s safety profile was adequate to support approval, 9–9 that…

You must be logged in to read/download the full post.